MedTrace Logo

Investigation of a Novel Cosmeceutical to Reduce the Visible Signs of Cutaneous Aging

NCT02877758 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-08-25

No results posted yet for this study

Summary

Tomorrowlabs has developed a revolutionary cosmeceutical formulation to rejuvenate aging skin. Tomorrowlabs is conducting this research to study whether this cosmeceutical can reduce the visible signs of cutaneous aging.

Conditions

  • Aging

Interventions

OTHER

Tomorrowlabs cosmeceutical formulation

OTHER

Sham cosmeceutical formulation

Sponsors & Collaborators

  • Tomorrowlabs GmbH

    lead INDUSTRY

Principal Investigators

  • Raphael Wenny, MD · JKU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-02-28
Completion
2017-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02877758 on ClinicalTrials.gov